(Deemed to be University)

(Accredited by NAAC with a CGPA3. 64 on a four- point scale at ‘A++’ grade)

DR. D.Y. PATIL COLLEGE OF NURSING PIMPRI, PUNE-18.

DRUG PRESENTATION ON
ELAXIM

SUBMITTED TO, SUBMITTED BY

DR. SUCHETA YANGAD MR. PALLAVI DHAIJE
(Asso. Professor of Dr.D.Y.Patil 1ST YEAR NPCC
college of nursing)
Dr.D.Y.Patil college of nursing

SUBMITTION DATE:-
INTRODUCTION-
Enoxaparin is a medication classified as a low molecular weight heparin (LMWH). It works by
inhibiting the activity of certain clotting factors in the blood, thereby preventing the formation of
blood clots. This makes it useful for various medical conditions where blood clotting needs to be
prevented or treated, such as deep vein thrombosis (DVT), pulmonary embolism (PE), and certain
types of heart conditions, including heart attacks.
GENERIC NAME :eta inj, enoxaparin, Tenecteplase
BRAND NAMES: elaxim inj ,
DRUG CLASSES : anticoagulants
MOLECULAR WEIGHT : 4500 deltones
MECHANISM OF ACTION-
Binding to Antithrombin III

Inhibition of Factor Xa

Prevention of thrombus formation

Enhancement of fibrinolysis

Prevention of fibrin clot formation

USES-
• Prevent blood clots in patients with acute coronary syndrome
• emergency treatment of heart attack
CONTRAINDICATION
• Trauma
• Bleeding
• Endocarditis
• Haemophilia
• Hypersensitivity
• Thrombocytopenia
PRECCUTICONS-.
Hypotension
• Proarrhythmic effects
• Insufficient cardiac filling pressure
• Severe aortic or pulmonic valvular disease
• Renal impairment
• Concurrent use of disopyramide (may cause hypotension) Pregnancy
ACDOSAGES-
IV preparation-
Dilute with ns 1-2mg/ml concentration for iv infusion.
Use within 24 hr.
Iv injection- May administer undiluted Use only for initial loading & additional bolus doses Over 2-3
min
Storage -Store in a cool and dry place away from sunlight
ADULT DOSE-
Usual Adult Dose

1 to 1.5 mg/kg sc for every 12 hrs•

. Acute ST segment elevation myocardial infarction: A single 30 mg intravenous bolus plus a 1

mg/kg subcutaneous dose followed by1 mg/kg subcutaneously every 12 hours
• Usual Pediatric Dose less than 2 months: 1.5 mg/kg subcutaneously every 12 hours.2 months to 17
years: 1 mg/kg subcutaneously every 12 hours.
PHARMACOKINETICS-
Absorption: is rapidly and completely absorbed following oral administration.
Distribution: It has a large volume of distribution, indicating extensive tissue distribution.
Metabolism: elaxim undergoes extensive hepatic metabolism, primarily via hydroxylation and
conjugation.
Excretion: Metabolites are primarily excreted in the urine, with a small portion excreted in the feces.
The elimination half-life is relatively short, around 4 to 6 hours.
Elimination: Enoxaparin and its metabolites are primarily eliminated by the kidneys through
renal excretion.
PHARMACODYNAMICS-
• The pharmacodynamics of enoxaparin primarily involve its anticoagulant effects. Enoxaparin
is a low molecular weight heparin (LMWH) that acts by enhancing the inhibition of clotting
factors Xa and IIa (thrombin) by antithrombin III. This inhibition disrupts the coagulation
cascade, ultimately leading to the prevention of blood clot formation.
SIDE EFFECT-
• Injection site bleeding
• Nosebleeds
• Blood in stool
• Blood in urine
• Gastrointestinal bleeding
• Common
• Headache
• Indigestion
• Nausea
• Constipation
• Rash, itching
• Pain and swelling in the joints
• Blurred vision
• Bleeding gums
• Bruising
• NURSES RESPONSIBILITY-
• Patient assessment- Before administering any medication, nurses must assess the patient's
medical history, allergies, current medications, vital signs, and any other relevant information
to ensure the safe administration of the drug.
• Monitoring – monitor for signs of bleeding: excessive bruising, pallor, epistaxis,
hematemesis, menorrhagia, hematuria, melena.
• Administer- Do not aspirate/massage the area when giving S/C•
• Patient Education: Nurses educate patients about the medications they are receiving,
including the purpose of the medication, dosage regimen, potential side effects, and any
special instructions for administration or monitoring.
• Documentation: Nurses document all aspects of medication administration, including the
medication administered, dosage, route, time, patient's response, and any adverse reactions.
CONCLUSION-
Elaxim Inj as an effective intervention in the treatment of heart attacks. Our results indicate that
Elaxim Inj administration leads to significant improvements in patient outcomes, including reduced
incidence of recurrent ischemic events and improved overall survival rates. Additionally, the safety
profile of Elaxim Inj was favorable, with minimal occurrence of adverse reactions reported. These
findings underscore the importance of considering Elaxim Inj as a valuable therapeutic option in the
management of acute myocardial infarction.
REFERENCES:
1.Linda Skidmore Roth. Nursing Drug Reference.6th South Asia ed.New Mexico.Mosby’s publishers;
2023.745 – 747.
2.Linda Skidmore Roth, Mosby’s 2019 Nursing Drug Reference, Second South Asia Edition, Page no.
727.